<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04281745</url>
  </required_header>
  <id_info>
    <org_study_id>MT03-KR19GBL404</org_study_id>
    <nct_id>NCT04281745</nct_id>
  </id_info>
  <brief_title>Long-term Open-label Treatment of Moderate to Severe Glabellar Lines With CORETOX®</brief_title>
  <official_title>A Single-arm Trial, Open-label, Repeated, Long-term, Multi-center, Phase IV Clinical Trial to Evaluate the Long-term Efficacy and Safety of Repeat Treatment of Glabellar Lines With CORETOX®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medy-Tox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medy-Tox</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the long-term safety and efficacy of CORETOX in the treatment of
      moderate to severe glabellar lines.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 17, 2019</start_date>
  <completion_date type="Anticipated">March 16, 2022</completion_date>
  <primary_completion_date type="Actual">June 17, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator-rated improvement rate of glabellar lines at maximum frown at Week 4 of each treatment cycle</measure>
    <time_frame>At Week 4 of each cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment).</time_frame>
    <description>Improvement rate: improvement of Facial Wrinkle Scale score from 3 (moderate) or 4 (severe) to 0 (none) or 1 (mild)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject-rated improvement rate of glabellar lines at maximum frown</measure>
    <time_frame>Every 4 weeks in each treatment cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Subject-rated satisfaction at each cycle after treatment</measure>
    <time_frame>Every 4 weeks in each treatment cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment on-set date</measure>
    <time_frame>From baseline to Day 7 of each cycle (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment duration</measure>
    <time_frame>From on-set date to next treatment (each cycle lasts until re-treatment, where re-treatment is possible after 90 Days from the last treatment).</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants who experienced an adverse event</measure>
    <time_frame>Baseline to Day 720</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with binding and neutralizing antibodies</measure>
    <time_frame>Screening and Day 720</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Glabellar Frown Lines</condition>
  <arm_group>
    <arm_group_label>Coretox®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botulinum toxin type A to be intramuscularly injected at 4 sites of corrugator muscle and at 1 site of procerus muscle with 0.1 mL (4U) at each site, for a total of 0.5 mL (20U). The administration of the investigational product was performed once at the start of each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CORETOX Inj</intervention_name>
    <description>Clostridium botulinum type A (Hall group); a lyophilized white power for injection with a colorless transparent vial. colorless transparent solution when dissolved with saline.</description>
    <arm_group_label>Coretox®</arm_group_label>
    <other_name>Botulinum toxin type A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged between 20 and 65

          -  Patients attaining ≥grade 2 (moderate) in the investigator's rating of the severity of
             glabella lines at maximum frown

          -  Patients who can comply with the study procedures and visit schedule

          -  Patients who voluntarily sign the informed consent

        Exclusion Criteria:

          -  Patients with medical conditions who may be at greater risk due to the administration
             of the investigational drugs (e.g.. diseases that may affect the neuromuscular action
             including Myasthenia Gravis, Lambert-Eaton Syndrome, Amyotrophic Lateral Sclerosis and
             motor neuropathy)

          -  Patients with the history of facial nerve paralysis or the symptoms of eyelid ptosis

          -  Patients who have received other procedures which may affect glabellar and forehead
             lines within 6 months

          -  Patients who have received other procedures which may affect glabellar and forehead
             lines within 6 months

          -  Patients who were injected with botulinum toxin within the past 3 months

          -  Patients with allergy or hypersensitivity to the investigational drugs or their
             components

          -  Patients who have bleeding tendency or taking anti-coagulant

          -  Female subjects who are pregnant or lactating. Female subjects of childbearing age who
             have a plan to get pregnant during the study period, or do not use available
             contraceptive methods (Women of childbearing age should have negative urine pregnancy
             test results at baseline visit (0 week) prior to the first injection.)

          -  Patients with skin disorders or infection at the injection site

          -  Patients who are participating in other clinical trials or have participated in other
             clinical trials 30 days before screening

          -  Patients who are unable to communicate or follow the instructions

          -  Patients who are not eligible for this study based on the judgment of an investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 17, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 24, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

